'Designer' pill set to cut melanoma deaths by almost two-thirds

A new era in the treatment of skin cancer was heralded by doctors yesterday as they unveiled what has been called the biggest breakthrough in 30 years.

A twice-a-day pill that targets a faulty gene present in melanoma, the deadliest form of skin cancer, has been shown to reduce the risk of death by almost two-thirds in patients with the advanced form of the disease.

James Larkin of the Royal Marsden Hospital in London, the principal investigator in the UK, said: "This is a pivotal moment. Without question, the results of this trial represent a turning point in the treatment of this disease."

Professor Richard Marais of the Institute of Cancer Research, who first demonstrated the importance of the gene in melanoma, said: "This is the biggest breakthrough in melanoma treatment in more than 30 years. The results demonstrate for the first time that a targeted therapy can work and will change our approach to treating this disease. It is an enormous advance in the field."

The drug is the first "personalised" treatment for melanoma, designed to target cases of the disease which carry the faulty gene, called a BRAF mutation, which account for about half of all cases. As such, it marks a milestone in the transformation of cancer medicines from blunderbuss treatments for everybody to designer drugs tailored to individual cases.

Melanoma has been the fastest rising cancer in the UK over the past 25 years, with more than 10,000 cases a year and 2,000 deaths. It is the second most common cancer in young adults aged 15 to 34 and affects twice as many women as men, although more men die of it.

A typical victim is the pale-skinned office worker who spends two weeks broiling on a Mediterranean beach until their skin is red and blistered. Covering up in the midday sun and using high-factor sun cream is the best defence against the cancer.

The international drug trial involved 670 patients in the US, Canada, Europe and Australia, including 50 in the UK. It showed survival rates at six months increased from 64 per cent for those on standard chemotherapy to 84 per cent on the new drug, called vemurafenib.

The improvement was so dramatic that three months into the trial participants receiving standard chemotherapy were offered the chance to switch to vemurafenib.

The findings were published yesterday by the New England Journal of Medicine and were presented at the annual meeting of the American Society for Clinical Oncology in Chicago.

Dr Larkin said: "For the last few decades we have treated melanoma with chemotherapy and it didn't work very well. Now that we understand the biology of the disease we can target the genes responsible. We know the BRAF mutation drives the disease."

Roche, the Swiss multinational, developed the drug with its partner Plexxikon, a biotech company which is also developing a test to screen patients for the BRAF mutation.

The companies are likely to apply for a licence for vemurafenib later this year. It is expected to cost tens of thousands of pounds per patient per year.

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Arts and Entertainment
Ben Stiller as Derek Zoolander in the leaked trailer for Zoolander 2
film
Sport
footballArsenal take the Community Shield thanks to a sensational strike from Alex Oxlade-Chamberlain
Arts and Entertainment
Gemma Chan as synth Anita in Humans
film
News
Keeping it friendly: Tom Cruise on ‘The Daily Show’ with Jon Stewart
people
Arts and Entertainment
Ensemble cast: Jamie McCartney with ‘The Great Wall of Vagina’
artBritish artist Jamie McCartney explains a work that is designed to put women's minds at rest
News
Republican Presidential Candidate Donald Trump
people
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: IT Support Engineer

    £18000 - £26000 per annum: Recruitment Genius: This is an opportunity for an I...

    Recruitment Genius: Project Assistant

    £17000 per annum: Recruitment Genius: They are a leading company in the field ...

    Recruitment Genius: DBA Developer - SQL Server

    £30000 - £35000 per annum: Recruitment Genius: This is an exciting opportunity...

    Recruitment Genius: Office Manager

    £26041 - £34876 per annum: Recruitment Genius: There has never been a more exc...

    Day In a Page

    Turkey-Kurdish conflict: Obama's deal with Ankara is a betrayal of Syrian Kurds and may not even weaken Isis

    US betrayal of old ally brings limited reward

    Since the accord, the Turks have only waged war on Kurds while no US bomber has used Incirlik airbase, says Patrick Cockburn
    VIPs gather for opening of second Suez Canal - but doubts linger over security

    'A gift from Egypt to the rest of the world'

    VIPs gather for opening of second Suez Canal - but is it really needed?
    Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

    Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

    Fashion editor, Alexander Fury, applauds a man who clearly has more important things on his mind
    The male menopause and intimations of mortality

    Aches, pains and an inkling of mortality

    So the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
    Man Booker Prize 2015: Anna Smaill - How can I possibly be on the list with these writers I have idolised?

    'How can I possibly be on the list with these writers I have idolised?'

    Man Booker Prize nominee Anna Smaill on the rise of Kiwi lit
    Bettany Hughes interview: The historian on how Socrates would have solved Greece's problems

    Bettany Hughes interview

    The historian on how Socrates would have solved Greece's problems
    Art of the state: Pyongyang propaganda posters to be exhibited in China

    Art of the state

    Pyongyang propaganda posters to be exhibited in China
    Mildreds and Vanilla Black have given vegetarian food a makeover in new cookbooks

    Vegetarian food gets a makeover

    Long-time vegetarian Holly Williams tries to recreate some of the inventive recipes in Mildreds and Vanilla Black's new cookbooks
    The haunting of Shirley Jackson: Was the gothic author's life really as bleak as her fiction?

    The haunting of Shirley Jackson

    Was the gothic author's life really as bleak as her fiction?
    Bill Granger recipes: Heading off on holiday? Try out our chef's seaside-inspired dishes...

    Bill Granger's seaside-inspired recipes

    These dishes are so easy to make, our chef is almost embarrassed to call them recipes
    Ashes 2015: Tourists are limp, leaderless and distinctly UnAustralian

    Tourists are limp, leaderless and distinctly UnAustralian

    A woefully out-of-form Michael Clarke embodies his team's fragile Ashes campaign, says Michael Calvin
    Blairites be warned, this could be the moment Labour turns into Syriza

    Andrew Grice: Inside Westminster

    Blairites be warned, this could be the moment Labour turns into Syriza
    HMS Victory: The mystery of Britain's worst naval disaster is finally solved - 271 years later

    The mystery of Britain's worst naval disaster is finally solved - 271 years later

    Exclusive: David Keys reveals the research that finally explains why HMS Victory went down with the loss of 1,100 lives
    Survivors of the Nagasaki atomic bomb attack: Japan must not abandon its post-war pacifism

    'I saw people so injured you couldn't tell if they were dead or alive'

    Nagasaki survivors on why Japan must not abandon its post-war pacifism
    Jon Stewart: The voice of Democrats who felt Obama had failed to deliver on his 'Yes We Can' slogan, and the voter he tried hardest to keep onside

    The voter Obama tried hardest to keep onside

    Outgoing The Daily Show host, Jon Stewart, became the voice of Democrats who felt the President had failed to deliver on his ‘Yes We Can’ slogan. Tim Walker charts the ups and downs of their 10-year relationship on screen